What Агапурин treats: main uses and benefits

This medication is commonly used in adult patients with chronic occlusive arterial disease for the symptomatic relief of intermittent claudication. It is used to help address symptoms related to circulation problems, particularly aching, cramping, and tiredness in the hands and feet. The primary therapeutic focus is on providing supportive relief for these symptoms that interfere with daily functioning.

The medication plays a role in addressing conditions characterized by chronic, stable symptoms associated with peripheral vascular health. It may assist with maintaining functional stability when symptoms escalate. By playing a role in easing the painful symptoms induced by exercise, the medication may assist with an increased pain-free walking distance. This enhancement contributes to easing day-to-day comfort during symptomatic periods. It is commonly used to help with painful manifestations of chronic occlusive arterial disease and related functional limitations.

---

Quick Fact: Relief for Exertional Limb Pain Агапурин is used to help with the pain, cramping, and fatigue in the limbs that is caused by poor circulation during walking, supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile for Агапурин (Pentoxifylline)

Official regulatory documents define strict population eligibility criteria for Pentoxifylline, primarily restricting use based on acute clinical conditions, bleeding risk, and age. The medicine is primarily indicated for use in adult patients with chronic occlusive arterial disease.

Classification	Population Group or Condition
Absolute Contraindicated	Known hypersensitivity to pentoxifylline or other methylxanthines; recent cerebral or retinal hemorrhage; acute myocardial infarction; active or recent peptic ulceration; severe coronary artery disease.
Not Recommended	Children and adolescents under 18 years of age (safety/efficacy not established); pregnant or breastfeeding women.
Restricted Use	Patients with severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment; use in these groups is often not recommended or requires close monitoring.

Use requires caution in the elderly due to potential for reduced organ function. The regulatory profile specifically restricts use in situations where the risk of bleeding is heightened or cardiovascular stability is severely compromised.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Pentoxifylline (Агапурин), strictly based on governmental regulatory labeling. The co-administration profile is defined by pharmacokinetic and pharmacodynamic interactions.

Documented Pharmacodynamic Interactions

Co-administration with several medicinal product classes can result in additive effects. When combined with antihypertensive drugs (e.g., ACE inhibitors, Nifedipine), there is a documented additive effect on blood pressure reduction. Co-administration with antidiabetic agents (e.g., Insulin or oral hypoglycemics) carries the potential for enhanced hypoglycemic action. Furthermore, there is an additive risk of hemorrhage when combined with Vitamin K antagonists (e.g., Warfarin) or other platelet aggregation inhibitors (e.g., Aspirin, NSAIDs).

Pharmacokinetic and Exposure Alterations

Certain substances affect the drug’s metabolic profile. Strong CYP1A2 inhibitors, such as Ciprofloxacin and Fluvoxamine, officially increase the exposure of Pentoxifylline and its active metabolite. Similarly, co-administration with Cimetidine increases the steady-state plasma concentration of the medicine. Co-administration with Theophylline is documented to increase Theophylline plasma levels, potentially leading to toxicity. Regulatory guidance strongly cautions against or prohibits combinations with Riociguat.

Food and Population-Specific Notes

Taking the extended-release tablet with food results in a measurable increase in the drug's overall exposure (AUC and Cmax). Documentation also indicates that exposure to the medicine and its metabolites is significantly increased in patients with documented hepatic or severe renal impairment.

The mechanism of Агапурин (Pentoxifylline) involves altering the flow characteristics of blood and modulating inflammatory processes at the cellular and molecular level.

Cellular Signaling via Phosphodiesterase Inhibition

The drug's action begins with the non-selective inhibition of Phosphodiesterase (PDE) enzymes, particularly in blood cells. This interaction prevents the breakdown of the signaling molecule cyclic Adenosine Monophosphate (cAMP). The resulting sustained elevation of intracellular cAMP acts as a crucial biochemical trigger for subsequent physiological effects, including the activation of protein kinases.

Hemorheology and Microcirculatory Alteration

This mechanistic domain describes how molecular action translates into systemic changes in blood flow. Increased cAMP enhances the flexibility of red blood cells (erythrocytes) and suppresses the adhesion of white blood cells and platelets. It also reduces the plasma concentration of fibrinogen through modulation of the fibrinolytic pathway. These combined effects lead to a decrease in blood viscosity, and affect microcirculation and tissue perfusion.

Suppression of Pro-inflammatory Mediators

This pathway describes the modulation of immunological processes. By acting through the cAMP pathway in immune cells, the drug suppresses the activity of the transcription factor NF-κB. This action limits the production and release of major inflammatory proteins, such as Tumor Necrosis Factor-alpha (TNF-α), resulting in modulation of chronic vascular inflammation.

The use of Агапурин (Pentoxifylline) is governed by specific instructions concerning its administration route, dosage, frequency, and duration.

Administration and Dosage Patterns

The medicine is available for systemic use as oral modified-release tablets (400 mg strength) and as a solution for intravenous infusion. Oral administration is the primary route for long-term management.

Feature	Official Dosing Guideline
Standard Adult Regimen	400 mg administered three times a day (TID), resulting in a 1200 mg total daily dose.
Administration Timing	Oral tablets must be taken with meals or immediately after eating to help reduce potential gastrointestinal irritation.
Tablet Handling	The modified-release tablets must be swallowed whole with water and should not be crushed, chewed, or broken, which is necessary to maintain the controlled-release properties.
Therapy Duration	The maximum therapeutic effect may take 2 to 4 weeks to become evident, and treatment is typically continued for a minimum of 8 weeks or as part of a long-term plan.

Special Procedural Conditions

Dose adjustments are required for patients with renal or hepatic impairment. For individuals with severe renal impairment (creatinine clearance below 30 mL/min), a reduction in the daily dose is required, typically to 400 mg once a day. Dose reduction is also necessary for patients with severe hepatic impairment. If adverse effects related to the central nervous system or digestive system develop, the dosage may be lowered to 400 mg twice daily. If a dose is missed, it is advised not to take a double dose to make up for the omission.

Research evidence / Overview of Studies for Агапурин (Pentoxifylline)

---

Evidence for use in Intermittent Claudication

The primary clinical context where Агапурин (Pentoxifylline) was studied for is Intermittent Claudication (IC), a condition characterized by cramping pain in the legs, usually while walking, due to reduced blood flow. Research in this area has relied mainly on Randomized Controlled Trials (RCTs). The outcomes related to systemic or functional imbalance research examined included the Pain-Free Walking Distance (PFWD) and Total Walking Distance (TWD), as monitored during standardized treadmill tests. Studies generally included adult patients with chronic circulatory disorders, specifically those with stable intermittent claudication.

The findings describe patterns observed in the studies regarding walking capacity. Some trials reported that changes in measured walking distance were tracked between the Pentoxifylline group and the placebo group, yet the findings were mixed across the full body of evidence. Studies monitoring the Ankle-Brachial Pressure Index (ABI) often reported that measurements of this index showed no difference between the treatment group and the placebo group. Overall, this research provides insight into short-term changes in functional measures.

---

Analysis of Evidence Quality and Consistency

The research base was evaluated in systematic reviews and meta-analyses. The evidence suggesting that Pentoxifylline may help with walking distance is limited and has been assigned a classification of low certainty. This is due to scientific reviews highlighting high heterogeneity (meaning a significant lack of consistency) across the different RCTs. The evidence quality varies across studies, and scientific certainty regarding the precise role of Pentoxifylline in measured walking ability remains low to moderate.

---

What is Still Uncertain about Агапурин Research

Despite the controlled trials, several significant research limitation frames exist. Because follow-up durations were limited, the long-term effects are not fully established. Limited information for long-term outcomes means it is unclear if the medication influences hard clinical endpoints such as reducing the need for amputation or preventing major vascular events. Furthermore, due to the sample sizes were modest in some key studies and comparative evidence is lacking against other approaches was studied for IC, the precise role of the medication in the current evidence landscape is not fully established.

Key Studies & References

1. Pentoxifylline Extended-Release Tablets - FDA DailyMed Drug Label
2. Pentoxifylline - NIH MedlinePlus Drug Information (Used for Indication Context)
3. NICE Guideline [CG147] - Peripheral arterial disease: diagnosis and management (Research Role)

Common questions about Агапурин (FAQ)

---

Q: Are Agapurin and Trental the same medicine?

A: Yes. Агапурин and Trental are different trade names used for medications that contain the same active substance, which is Pentoxifylline. Official drug documents confirm that the core purpose and ingredient are identical.

---

Q: How quickly will I notice the effects of Agapurin?

A: Regulatory documents indicate that the maximum therapeutic benefit may take two to four weeks to become evident. In clinical trials, achieving the full desired result often required the treatment to be continued for up to two months or as part of a longer-term plan.

---

Q: Can Agapurin cause issues with blood pressure?

A: Regulatory labeling lists hypotension (low blood pressure) and arrhythmias (irregular heartbeat) as documented, although less common, serious adverse reactions. The regulatory label contains warnings about these effects, which is why caution is noted for patients with pre-existing heart conditions.

---

Q: Why might I feel dizzy when taking Agapurin?

A: Regulatory documents note that dizziness and headache are among the most frequently documented side effects related to the nervous system. While the official documents confirm this occurrence, they do not detail the precise biological reason for why this effect happens.

---

Q: Does Agapurin affect my attention or ability to drive?

A: Official regulatory warnings include information about potential effects on attention or driving ability. This warning is included because the medicine may cause side effects such as dizziness.

---

Q: Can I take Agapurin if I have diabetes?

A: Co-administration with antidiabetic agents (such as insulin or oral hypoglycemic drugs) may lead to an enhanced hypoglycemic action (a further lowering of blood sugar). Official information advises caution when combining the medicine due to this potential interaction.

---

Q: Can Agapurin be taken simultaneously with alcohol?

A: Information on the direct interaction between this medication and alcohol is not always explicitly detailed in core regulatory documents. However, because the drug can cause side effects like dizziness, consuming alcohol may increase the risk or severity of such effects.

---

Q: Why does the leaflet say Agapurin is not for pregnant women?

A: The medicine is assigned to Pregnancy Category C in regulatory labeling. This classification indicates that controlled data on its use in human pregnancy is absent, and for this reason, it is generally not recommended for use during pregnancy.

---

Q: Why must I take Agapurin with caution if I have heart problems?

A: The medicine is contraindicated (should not be used) in patients with acute myocardial infarction or severe coronary artery disease. The official label contains warnings regarding the risk of serious adverse reactions like severe hypotension or arrhythmias, which contributes to these restrictions.

---

Q: Is there research on Agapurin use in children?

A: The official regulatory profile states that the medicine is not advised for use in patients under 18 years of age. This is because official documents conclude that its safety and efficacy have not been fully established in this age group.

---

Q: What is 'Intermittent Claudication Syndrome,' for which Agapurin is prescribed?

A: Intermittent Claudication is the primary condition the medicine was studied for. It is described in the official medical context as a condition characterized by cramping pain in the legs that typically occurs while walking, caused by reduced blood flow to the limbs.

---

Q: What do studies say about the stomach side effects of Agapurin?

A: The most frequently reported side effects are related to the gastrointestinal system, including nausea, vomiting, and abdominal discomfort. This risk is why official guidance advises taking the tablets with food to help reduce potential irritation.

---

Q: Do I need to change my diet when taking Agapurin?

A: The official label contains the instruction that tablets should be taken with meals or immediately following food to help reduce potential gastrointestinal irritation. Regulatory documents do not generally advise other specific dietary changes.

---

Q: Can Agapurin interact with herbal supplements?

A: Official regulatory documentation requires caution when combining the medicine with any agents that affect blood clotting. This cautionary guidance is broad enough to include certain herbal supplements that have documented blood-thinning properties.

---

Q: What are the general expectations from a course of Agapurin treatment?

A: The maximum therapeutic effect is generally expected to become evident within 2 to 4 weeks of treatment. Research evidence primarily examined changes in walking distance for patients with chronic circulatory disorders.

---

Q: Could Agapurin be ineffective for some people?

A: The scientific evidence base, as evaluated in systematic reviews, has reported mixed findings across different studies. This lack of consistency, sometimes classified as low certainty, means the evidence for a functional benefit is not guaranteed across all patients.

---

Q: Why do some people consider Agapurin outdated?

A: Systematic reviews have evaluated the research base and highlighted a classification of low certainty and high heterogeneity (inconsistency) in the results of clinical trials. This profile often limits its established role in the current evidence-based medicine landscape.

How to Store and Dispose of Agapurin?

Agapurin (pentoxifylline) must be stored at a Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F and 77 F). The medicine must be protected from light and stored away from excess heat and moisture.

It is required to keep the product in the original container and ensure it is tightly closed. The official labeling prohibits freezing the medicine. For safety, Agapurin must always be kept out of the sight and reach of children.

Regarding disposal, any unused or expired medicine must be discarded according to local regulations. It is officially stated that the product should not be disposed of in wastewater or household trash.